CHICAGO, Dec. 4, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen Idec Inc. (Nasdaq:BIIB-Free Report), Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report) and Amgen Inc. (Nasdaq:AMGN-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday's Analyst Blog:
Encouraging Alzheimer's Data for Biogen (BIIB)
Biogen Idec Inc.'s (Nasdaq:BIIB-Free Report) shares were up 6.4% immediately after the company reported encouraging interim results from an early-stage study on its anti-amyloid beta antibody, BIIB037. Biogen is evaluating BIIB037 for the treatment of Alzheimer's disease. The data was presented at the Deutsche Bank BioFEST conference.
According to reports from various sources, interim results from the phase Ib study, which was conducted on 194 Alzheimer patients demonstrated both dose- and time-dependent reductions in beta-amyloid levels in the brain. Moreover, a statistically significant improvement in cognition was observed after 54 weeks of treatment. However, there were some side effects called amyloid related imaging abnormalities (ARIA). Biogen intends to move the candidate into phase III based on the promising results.
We are pleased with the results from the early-stage study. As per data provided by the Alzheimer's Association, Alzheimer's, the most common form of dementia, affects nearly 5 million people in the U.S. aged 65 years and above.
The Alzheimer's disease market offers huge commercial potential and a successfully developed product could generate billions of dollars in sales. However, we note that the successful development of therapies for the treatment of Alzheimer's disease is challenging and several companies including Eli Lilly (NYSE:LLY-Free Report) have faced setbacks.
Currently, Eli Lilly and AstraZeneca (NYSE:AZN-Free Report) are jointly developing a treatment for Alzheimer's disease. Earlier this week, the companies announced the initiation of the phase II/III AMARANTH study on AZD3293 (LY3314814). The study will evaluate the safety and efficacy of AZD3293 in comparison to placebo for the treatment of early Alzheimer's disease.
Biogen currently carries a Zacks Rank #1 (Strong Buy). An equally well-ranked stock in the biotech sector is Amgen Inc. (Nasdaq:AMGN-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on BIIB - FREE
Get the full Report on LLY - FREE
Get the full Report on AZN - FREE
Get the full Report on AMGN - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Logo -
http://photos.prnewswire.com/prnh/20101027/ZIRLOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-zacks-analyst-blog-highlights-biogen-idec-eli-lilly-astrazeneca-and-amgen-300004855.html
SOURCE Zacks Investment Research, Inc.
Share this article